A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: Efficacy and safety results from the phase II, multi-center ANNIE study

Guochen Liu; Yanling Feng; Jing Li; Ting Deng; Aijun Yin; Lei Yan; Min Zheng; Ying Xiong; Jundong Li; Yongwen Huang; Chuyao Zhang; He Huang; Ting Wan; Qidan Huang; An Lin; Jie Jiang; Beihua Kong; Jihong Liu

doi:10.1016/j.eclinm.2022.101767

A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: Efficacy and safety results from the phase II, multi-center ANNIE study

EClinicalMedicine. 2022 Nov 30:54:101767. doi: 10.1016/j.eclinm.2022.101767. eCollection 2022 Dec.

Authors

Guochen Liu¹, Yanling Feng¹, Jing Li¹, Ting Deng¹, Aijun Yin², Lei Yan³, Min Zheng¹, Ying Xiong¹, Jundong Li¹, Yongwen Huang¹, Chuyao Zhang¹, He Huang¹, Ting Wan¹, Qidan Huang¹, An Lin⁴, Jie Jiang², Beihua Kong², Jihong Liu¹

Affiliations

¹ Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Road East, Guangzhou, 510060, China.
² Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, 107 West Wenhua Road, Jinan, 250012, China.
³ The First Affiliated Hospital of Jinan University, 613 Huangpu Avenue West, Guangzhou, 510630, China.
⁴ Fujian Provincial Cancer Hospital, No. 91, Fengpanma Road, Fuma Road, Fuzhou, 350014, China.

Abstract

Background: Patients with platinum-resistant recurrent ovarian cancer (PROC) face poor prognosis and limited treatment options. Single-agent antiangiogenics and poly (ADP-ribose) polymerase (PARP) inhibitors both show some activities in platinum-resistant diseases. The ANNIE study aimed to evaluate the efficacy and safety of the novel combination of the PARP inhibitor niraparib and the antiangiogenic anlotinib in patients with PROC.

Methods: ANNIE is a multicentre, single-arm, phase 2 study (ClinicalTrials.gov identifier NCT04376073) conducted at three hospitals in China. Eligible patients had histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal cancer that recurred within 6 months of last platinum-based chemotherapy. Patients with prior PARP inhibitor exposure were excluded. The enrolled patients received oral niraparib 200 mg or 300 mg (baseline body weight-directed) once daily continuously and anlotinib 10 mg (12 mg before protocol amendment) once daily on days 1-14 of each 21-day cycle until disease progression or intolerable toxicity. The primary endpoint was objective response rate (ORR).

Findings: Between May 22, 2020, and April 22, 2021, 40 patients were enrolled and treated. Thirty-six patients underwent post-baseline tumour assessments. By data cut-off (January 31, 2022), median follow-up was 15.4 months (95% CI 12.6-17.7). Intention-to-treat ORR was 50.0% (95% CI 33.8-66.2), including one complete response and 19 partial responses. Median (95% CI) progression-free survival and overall survival were 9.2 months (7.4-11.9) and 15.3 months (13.9-not evaluable), respectively. Drug-related, grade ≥3 TEAEs were reported in 26 (68%) patients. There were no treatment-related deaths.

Interpretation: Niraparib plus anlotinib showed promising antitumour activity in patients with PROC. This oral combination warrants further investigation as a potential novel, convenient treatment option for patients with PROC.

Funding: Zai Lab (Shanghai) Co., Ltd; Jiangsu Chia Tai-Tianqing Pharmaceutical Co., Ltd; the National Natural Science Foundation of China (No. 82102783).

Keywords: Anlotinib; Niraparib; Ovarian neoplasia; Platinum-resistant.

Associated data

ClinicalTrials.gov/NCT04376073